KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Other Non-Current Assets (2018 - 2025)

Twist Bioscience (TWST) has disclosed Other Non-Current Assets for 8 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 9.86% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 9.86% year-over-year, with the annual reading at $2.4 million for FY2025, 51.53% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.4 million at Twist Bioscience, up from $2.4 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $6.9 million in Q1 2022, with the low at $1.5 million in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $3.0 million, with a median of $2.5 million recorded in 2025.
  • The sharpest move saw Other Non-Current Assets skyrocketed 351.11% in 2022, then crashed 72.4% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $1.6 million in 2021, then skyrocketed by 85.88% to $2.9 million in 2022, then skyrocketed by 85.42% to $5.4 million in 2023, then plummeted by 50.98% to $2.7 million in 2024, then decreased by 9.86% to $2.4 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.4 million, $2.4 million, and $3.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.